330156-50-8

Basic information

• Product Name: (R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol
• Synonyms: benzeneMethanol, 2,6-dichloro-3-fluoro-α-Methyl-, (alphaR)-;BenzeneMethanol,2,6-dichloro-3-fluoro-a-Methyl-, (aR)-;(R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol;Crizotinib InterMediate;Benzenemethanol, 2,6-dichloro-3-fluoro-α-methyl-, (αR)-;(R)-2,6-Dichloro-3-fluoro-alpha-methylbenzyl Alcohol;(R)-2,6-Dichloro-3-fluoro-α(R)-2,6-Dichloro-3-fluoro-α-methylbenzyl Alcohol
• CAS NO: 330156-50-8
• Molecular Formula: C₈H₇Cl₂FO
• Molecular Weight: 209.04
• EINECS: 1312995-182-4
• Product Categories: Chiral Compounds
• Mol File: 330156-50-8.mol
• Article Data: 23

Chemical Properties

• Melting Point: 41.0 to 45.0 °C
• Boiling Point: 261 °C
• Flash Point: 112 °C
• Appearance: /
• Density: 1.406
• Vapor Pressure: 0.00589mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• PKA: 13.30±0.20(Predicted)
• CAS DataBase Reference: (R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol(330156-50-8)
• EPA Substance Registry System: (R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol(330156-50-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 330156-50-8(Hazardous Substances Data)

Usage

Description

(R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol is an alcohol derivative characterized by its unique molecular structure featuring a dichloro-fluorophenyl group attached to a chiral carbon in the R configuration. (R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol serves as a crucial building block in the synthesis of various pharmaceuticals due to its distinct chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
(R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol is used as a pharmaceutical intermediate for the synthesis of Crizotinib (C785000), an anti-tumor molecular targeted drug. This intermediate plays a vital role in the development of drugs that specifically target tumor cells, offering a more precise and effective treatment approach for cancer patients.
In the synthesis of Crizotinib, (R)-1-(2,6-Dichloro-3-fluorophenyl)ethanol contributes to the formation of the drug's active pharmaceutical ingredient (API), which is designed to inhibit specific molecular targets within tumor cells. This targeted approach helps minimize side effects and improve the overall efficacy of the treatment.

InChI:InChI=1/C8H7Cl2FO/c1-4(12)7-5(9)2-3-6(11)8(7)10/h2-4,12H,1H3/t4-/m1/s1

Upstream product

• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 877397-67-6 1-(2,6-dichloro-3-fluorophenyl)ethyl acetate 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 

Downstream Products

• 877397-70-1 (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethyoxyl)-2-nitropyridine 
• 1370651-29-8 C₁₂H₉Cl₃FN₃O 
• 1201916-93-9 C₃₀H₃₄Cl₂FN₅O₇ 
• 1201916-63-3 {6-amino-5-[(2,6-dichloro-3-fluorophenyl)ethoxy]-pyridazin-3-yl}-N-(1-ethyl-6-oxo-1,6-dihydro-pyridin-3-yl)carboxamide 
• 1370651-32-3 C₂₂H₂₅Cl₃FN₃O₅ 
• 1370651-34-5 C₂₅H₃₀Cl₂FN₃O₇ 
• 1370651-36-7 6-[bis(tert-butoxycarbonyl)amino]-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridazine-3-carboxylic acid 
• 1370652-58-6 C₂₉H₃₂Cl₂FN₅O₇ 
• 1370652-56-4 {5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyridazin-3-yl}-N-(1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)carboxamide 
• 1365267-27-1 6-amino-5-[(1{R})-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-{N}-[4-[(3{R},5{S})-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide 
• 1370651-39-0 C₃₅H₄₁Cl₂FN₆O₇ 
• 1370651-40-3 C₃₅H₃₄Cl₂FN₅O₇ 
• 1370651-02-7 {5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyridazin-3-yl}-N-[4-(4-pyridylcarbonyl)phenyl]carboxamide 
• 1370651-42-5 C₃₁H₃₃Cl₂FN₄O₈ 

Relevant articles and documents

Biotransformation-mediated synthesis of (1S)-1-(2,6-dichloro-3- fluorophenyl)ethanol in enantiomerically pure form

An efficient four-step biotransformation-mediated synthesis of (1S)-1-(2,6-dichloro-3-fluorophenyl)ethanol in enantiomerically pure form is described. This compound is a key intermediate required for the preparation of PF-2341066, a potent inhibitor of c-

Preparation method of deuterated crizotinib and derivatives thereof

The invention relates to a preparation method of deuterated crizotinib and derivatives thereof, and belongs to the technical field of synthesis of medical compounds. Four deuterated crizotinib with different configurations are synthesized, the influence of the deuterated position and different chirality of the deuterated crizotinib on the biological activity and the drug metabolism property of thecrizotinib is investigated, and the result shows that the deuterated crizotinib and the crizotinib have similar anti-cancer activity. Compared with a deuterated crizotinib raceme and crizotinib, thedeuterated crizotinib has certain physicochemical property advantages, has good anticancer application prospects, and provides a new compound for synthesis of novel antitumor drugs. The resolution ofthe racemate phenylethanol derivative is a key step for synthesizing the deuterated crizotinib, the ee value of the racemate phenylethanol derivative directly influences the ee value of a final product, and the resolution method has the characteristics of easiness in operation, low cost and the like.

Chiral ferrocene phosphine-nitrogen-nitrogen tridentate ligand as well as preparation method and application thereof

The invention discloses a chiral ferrocene phosphine-nitrogen-nitrogen tridentate ligand as well as a preparation method and an application thereof. The general structural formula of the chiral ferrocene phosphine-nitrogen-nitrogen tridentate ligand is shown in formula (I) or formula (II), wherein R1 and R2 are independently selected from C1-C6 alkyl, C3-C6 cycloalkyl, aryl or heterocyclic aryl respectively; R3 is aryl, heterocyclic aryl or C1-C6 alkyl, and R4 is hydrogen, C1-C6 alkyl, aryl or heterocyclic aryl; the general structural formula in the formula (I) and the formula (II) contains animidazole group or a substituted benzimidazole group respectively; one or more substituent groups exist on a benzene ring of the substituted benzimidazole group, and each substituent group is independently selected from H or C1-C4 alkyl. The chiral ferrocene phosphine-nitrogen-nitrogen tridentate ligand has the advantages that the tridentate ligand is convenient to synthesize, exists in the air stably and can be coordinated with cheap metal to prepare a cheap metal catalyst, and the cheap metal catalyst is well applied to asymmetric hydrogenation reactions of ketone.